Notícias e Atividades da Tenaya Therapeutics

Tenaya Therapeutics é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

Tenaya Therapeutics é uma empresa listada sob o símbolo TNYA (US).

Veja o organograma con seus 30 executivos principais

Biografias mais buscadas da Tenaya Therapeutics

• Faraz Ali, Chief Executive Officer and Director
• Amy Burroughs, Director
• Jeffrey Walsh, Director

Recentes movimentos de executivos em Tenaya Therapeutics

• Tomohiro Higa antes Vice President, Finance, agora é Interim Principal Accounting Officer and Senior Vice President of Finance  (Notícia publicada em 10 de fevereiro de 2025).

Criar um alerta
para seguir os movimentos de executivos da Tenaya Therapeutics.

Tenaya Therapeutics possui 2.350 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e Johnson & Johnson Innovative Medicine DIA (Estados Unidos).

Popular M&A news in Biotecnologia

• Transcarent and Accolade have merged  (publicado em 9 de abril de 2025)..
• Kashiv BioSciences acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 7 de abril de 2025).
• Atsena Therapeutics acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 4 de abril de 2025).

Outros contatos sugeridos na indústria do Biotecnologia

• Kristina Burow - Director da Scholar Rock
• Steven Gillis - Chairman of the Board da VBI Vaccines
• Ali Behbahani - Non-Executive Director da Adaptimmune Therapeutics

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Tenaya Therapeutics

• Tenaya Therapeutics to Participate at the 35th Annual Piper Sandler Healthcare Conference | Tenaya Therapeutics, Inc.
• Tenaya Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update | Tenaya Therapeutics, Inc.
• Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy | Tenaya Therapeutics, Inc.
• Tenaya Therapeutics to Participate at the 21st Annual Morgan Stanley Global Healthcare Conference | Tenaya Therapeutics, Inc.
• Tenaya Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update | Tenaya Therapeutics, Inc.
• Tenaya Therapeutics to Participate at the 43rd Annual Canaccord Genuity Growth Conference | Tenaya Therapeutics, Inc.
• Tenaya Therapeutics Publishes Preclinical Data in Science Translational Medicine Detailing Discovery of HDAC6 Inhibitor for Treatment of Heart Failure | Tenaya Therapeutics, Inc.
• Tenaya Therapeutics Launches Operations of New Genetic Medicines Manufacturing Center to Support the Development of Potentially First-In-Class Cardiovascular Therapeutics | Tenaya Therapeutics, Inc.
• Tenaya Therapeutics to Present Preclinical Data on TN-301 HDAC6 Inhibitor at European Society of Cardiology Heart Failure 2022 Conference | Tenaya Therapeutics, Inc.
• Tenaya Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update | Tenaya Therapeutics, Inc.
• View more press releases Close

Redes sociais sobre Tenaya Therapeutics

• Tenaya Therapeutics na Wikipedia, Google News e Yahoo Finance
• Tenaya Therapeutics na LinkedIn, Twitter e YouTube